{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-019065","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.038065+00:00","generated_at":"2026-05-17T02:34:10.617958+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MIRA Pharmaceuticals starts MAD Phase 1 of oral Ketamir-2; selects CIPN for Phase 2a","bullets":["Initiated multiple ascending dose (MAD) portion of Phase 1 trial for oral Ketamir-2 in healthy volunteers.","Selected chemotherapy-induced peripheral neuropathy (CIPN) as lead indication for planned Phase 2a study.","In SAD portion, no serious or dose-limiting adverse events; no clinically significant safety concerns.","Ketamir-2 is a non-scheduled oral analog of ketamine designed for once-daily dosing without psychoactive effects.","Preclinical data showed Ketamir-2 outperformed ketamine, gabapentin, and pregabalin in neuropathic pain models."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-019065","json":"https://secwatch.observer/filing/0001493152-25-019065.json","markdown":"https://secwatch.observer/filing/0001493152-25-019065.md","text":"https://secwatch.observer/filing/0001493152-25-019065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225019065/0001493152-25-019065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315225019065/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:34:10.617958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}